<DOC>
	<DOCNO>NCT01573520</DOCNO>
	<brief_summary>Controlling secondary hyperparathyroidism ( sHPT ) maintenance hemodialysis ( MHD ) patient cumbersome , partly due patient 's non-adherence prescribed drug . The main objective study ass whether integrated care ( IC ) approach , adherence data integrate decisional process , lead improved therapeutic control secondary hyperparathyroidsm high percentage bone metabolism target compare usual care ( UC ) approach , biological value represent main stem decisional process . The predefined hypothesis patient IC group reach iPTH target use 25 % less dose cinacalcet 6 month UC group .</brief_summary>
	<brief_title>Treatment Adhesion Dialysis Patients Treated With Cinacalcet</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Age &gt; 18 year Patients hemodialysis since 3 month Patients secondary hyperparathyroidism treat CinacalcetHCl stable dose ( 30mg/day ) least 1 month enrolment indication CinacalcetHCL therapy ( iPTH target value target value ) Patients secondary hyperparathyroidism indication treat CinacalcetHCL ( iPTH â‰¥ locally predefined target ) . In case , patient treat least 1 month stable dose CinacalcetHCL enrolment Intolerance CincalcetHCL Inability understand protocol Mental diseases Patients suffer cancer short life expectancy ( &lt; 6 month ) Patients plan parathyroidectomy Patients parathyroidectomy Patient already enrol CinacalcetHCL protocol Symptomatic hypocalcaemia total serum calcium &lt; 1.87 mmol/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>compliance</keyword>
	<keyword>dialysis</keyword>
	<keyword>hyperparathyroidism</keyword>
</DOC>